Literature DB >> 6167797

Supraventricular antidysrhythmic and electrophysiological effects of bepridil, a new antianginal agent.

E Winslow, K A Kane.   

Abstract

We investigated the potential antidysrhythmic effects of bepridil, a new antianginal agent, on dysrhythmias of supraventricular origin. Intravenous bepridil (5 mg/kg) suppressed dysrhythmias evoked by local application of aconitine to the left atria of anesthetized cats. After the aconitine-induced dysrhythmias had subsided, cardiac function was better maintained in animals given bepridil than in the controls. The effects of bepridil on the maximum following frequency (MFF) and transmembrane action potentials of isolated guinea pig atria and on cells displaying phase 4 depolarization were also examined. Both bepridil (5--120 microM) and verapamil (0.02--1 microM) induced a dose-dependent reduction in contractility of driven left atria, whereas only bepridil reduced MFF. The effects of bepridil (10--40 microM) on the cellular action potentials of left atria were a dose-dependent decrease in the maximum rate of depolarization of phase 0 associated with a reduction in action potential height and a marked prolongation of the action potential duration. In similar concentrations, bepridil reduced the spontaneous rate of the right atrium and reduced the slope of phase 4 depolarization. We conclude that the action of bepridil in suppressing supraventricular dysrhythmias may be partly explained by depression of automaticity together with a reduction in the intensity of the inward sodium current.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6167797     DOI: 10.1097/00005344-198107000-00001

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Potentiation of cardiodepressive action among calcium antagonists from different classes: evidence for a mechanism at the single calcium channel level.

Authors:  S Braun; N Frey; S Herzig; C Hilbert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-05       Impact factor: 3.000

2.  Effects of bepridil and lidocaine on the intraventricular conduction in acutely ischaemic and infarcted canine myocardium.

Authors:  H Hashimoto; N Satoh; M Nakashima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-12       Impact factor: 3.000

3.  Effects of the calcium entry blocker bepridil on repolarizing and pacemaker currents in sheep cardiac Purkinje fibres.

Authors:  F Berger; U Borchard; D Hafner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

4.  Bepridil and cetiedil. Vasodilators which inhibit Ca2+-dependent calmodulin interactions with erythrocyte membranes.

Authors:  P Agre; D Virshup; V Bennett
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

5.  Effects of bepridil on the electrophysiological properties of guinea-pig ventricular muscles.

Authors:  T Anno; T Furuta; M Itho; I Kodama; J Toyama; K Yamada
Journal:  Br J Pharmacol       Date:  1984-04       Impact factor: 8.739

6.  Effects of bepridil on transmembrane action potentials recorded from isolated canine cardiac tissues. Studies on normal and infarct-zone Purkinje fibres and ventricular muscle cells.

Authors:  K H Dangman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-05       Impact factor: 3.000

7.  Electrophysiological action of bepridil on atrioventricular accessory pathways.

Authors:  P Touboul; G Atallah; G Kirkorian; P Lavaud; J R Kieny; M P Mathieu; A Dellinger
Journal:  Br Heart J       Date:  1987-10

8.  Comparative clinical efficacy of bepridil, propranolol and placebo in patients with chronic stable angina.

Authors:  A P Rae; J M Beattie; T D Lawrie; I Hutton
Journal:  Br J Clin Pharmacol       Date:  1985-03       Impact factor: 4.335

Review 9.  Bepridil: a pharmacological reappraisal of its potential beneficial effects in angina and tissue protection following ischemia.

Authors:  R Massingham; P A Van Zwieten
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.